• Record shipment volume of 379,343 grams and 1,300+ orders during January and February 2023
• 152% increase in shipment volume for the first two months of 2023 over the monthly average shipments of 2022
• Adastra engages Hybrid Brand Management to expand sales coverage and product sell-through in BC, AB, SK, MB and ON
• Adastra in-house brand Endgame Extracts’ concentrates SKUs rank 2, 3, 4, 5, 7 and 8 of the top selling concentrates in British Columbia¹

LANGLEY, BC / ACCESSWIRE / March 16, 2023 / Adastra Holdings Ltd. (CSE:XTRX)(FRA:D2EP) (“Adastra” or the “Company“), a leading cannabis company focused on processing, adult-use and medical sales, organoleptic testing and analytical testing, announces record shipment volume for January and February 2023 and plans to further accelerate product and brand presence across Canada.

During January and February of 2023, Adastra shipped a record volume of 379,343 grams of cannabis products and achieved this result with over 1,300 orders, across a range of resellers who bought a variety of products, including its famous THC range and products under its Endgame brand, most notably “Astro Pink”, “Kush Mints”, “Tiger Cake x KK Mints”, “Double Hitter” as well as at least ten other popular SKUs. This shipment volume is an increase of 152% over the average monthly shipments during 2022.

Adastra has also engaged Hybrid Brand Management (“Hybrid“) to expand its sales coverage and product sell-through in British Columbia, Alberta, Saskatchewan, Manitoba, and Ontario, with regular in-store activations and staff product education sessions. Hybrid serves approximately 2,800 cannabis retailers in Canada.

“Adastra already has a strong presence across Canada for products we are licensed to sell, and we’re focused on covering more ground to build on the momentum we have achieved over the past year,” said Michael Forbes, CEO of Adastra. “The Hybrid team has deep relationships and understands the market, which we believe will further strengthen our position in key regions by promoting our in-house brands’ products in existing retailers and accelerating adoption of current and new SKUs in other retailers.”

“We’re thrilled to be working with Adastra,” said Scott Adair CEO of Hybrid Brand Management. “Adastra produces some of the best and most competitive cannabis products on the market, and we intend to help them become one of the leading producers in the country. Our team intends to grow their sales substantially by building distribution, boosting retailer and consumer engagement, and building brand equity.”

Adastra products are currently stocked in approximately 1,600 retailers. With 30 vaporizer cartridge SKUs and 16 concentrate SKUs, such as: shatter, THCa diamonds, sugar wax, full spectrum extract cartridges, and one infused pre-roll SKU.

Adastra currently has 26 Phyto Extractions products and 24 Endgame products on the market with 7 more being developed and prepared for commercialization. The Phyto Extractions and Endgame products are available for sale in British Columbia, Alberta, Saskatchewan, Manitoba, Ontario, Nova Scotia, Yukon, Northwest Territories, and Nunavut.

Adastra’s in-house brand Endgame Extracts’ concentrates SKUs are ranking as 2, 3, 4, 5, 7 and 8 of the top selling concentrates in British Columbia¹.

The Company intends to continue to work with retailers to enhance customer retention and lifetime value on existing products, whilst carefully assessing any new potential product development opportunities that may arise from either institutional or public clients, depending on the product category and relevant licence conditions.

^{1 Source: Headset data March 15, 2023}

About Adastra Holdings Ltd.

Adastra has become one of Canada’s leaders in the supply and manufacturing of ethnobotanical and cannabis products for lawful adult-use. It serves medical markets and engages in forward-looking therapeutic applications. With cannabis concentrate products sold through retailers at more than 1,600 locations across Canada, Adastra’s Phyto Extractions and Endgame Extracts brands are now well established with a solid distribution presence. As a Health Canada licensed facility, it specializes in extraction, distillation and manufacturing of a range of cannabis-derived products. Adastra partners with healthcare professionals and practitioners within the regulated environment to create products suitable for the medical cannabis market, with the ultimate aim of addressing the needs of patients. For more information, visit: www.adastraholdings.ca.

Contacts

Michael Forbes
CEO, Corporate Secretary & Director
(778) 715-5011
michael@adastraholdings.ca

Alyssa Barry
Media & Investor Relations
(604) 997-0965
ir@adastraholdings.ca

Forward-Looking Information

This news release contains forward-looking information within the meaning of applicable securities legislation in Canada concerning the business of the Company. Forward-looking information is based on certain key expectations and assumptions made by the management of the Company. Although the Company believes that the expectations and assumptions on which such forward looking information is based are reasonable, undue reliance should not be placed on the forward-looking information because the Company can give no assurance that they will prove to be correct. Forward looking information in this news release includes statements regarding, but not limited to: the intention to accelerate product and brand presence across Canada; the intention to expand the presence and effectiveness of the Company’s sales force; the belief that the appointment of Hybrid will generate growth for the Company; the expectation that Hybrid will grow the Company’s sales substantially by building distribution, boosting retailer and consumer engagement, and building brand equity; that additional products are being developed and prepared for commercialization; the Company intends to continue to work with retailers to enhance customer retention and value; and the intention to work closely with public and private stakeholders to serve patient needs that can reduce harm. There are numerous risks and uncertainties that could cause actual results and the Company’s plans and objectives to differ materially from those expressed in the forward-looking information. Important factors that could cause actual results to differ materially from those expressed in the forward-looking information include: changes in the laws and underlying regulations governing controlled substances and regulated products in Canada; the availability of a qualified workforce; changes in regulations or licensing affecting the Company’s business; patients’ access to products containing controlled substances and licensed products and other factors beyond the control of the Company. These and all subsequent written and oral forward-looking information are based on estimates and opinions of management on the dates they are made and are expressly qualified in their entirety by this notice. Except as required by law, the Company does not intend to update these forward-looking statements.

SOURCE: Adastra Holdings Ltd.

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

About Ryan Allway

Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.

Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, announces it will submit an updated briefing package to the U.S. Food & Drug Administration (“FDA”) to include additional supporting information and the data from the independent published study, titled “Omicron Spike Protein Is Vulnerable to Reduction” from the University of Toronto. The study evaluated the potential disruption of the SARS-CoV-2 virus spike protein by various FDA-approved mild anti-oxidants, which has shown that Bucillamine had the most potent effect on COVID-19 Omicron variants when compared to these anti-oxidants being explored as a potential treatment for COVID-19.

As recently reported by the Company, the FDA has granted the Company’s Type C meeting request to obtain agreement on the revised protocol endpoints for the Company’s Phase 3 clinical trial (the “Study”) (NCT04504734) to evaluate the safety and efficacy of Bucillamine, an oral drug with anti-inflammatory and antiviral properties, in patients with mild to moderate COVID-19. The goal date for the FDA to provide its written responses is March 7, 2023.

The Company is not making any express or implied claims that its product has the ability to eliminate or cure COVID-19 (SARS-2 Coronavirus) at this time.

About Revive Therapeutics Ltd.

Revive is a life sciences company focused on the research and development of therapeutics for infectious diseases and rare disorders, and it is prioritizing drug development efforts to take advantage of several regulatory incentives awarded by the FDA such as Orphan Drug, Fast Track, Breakthrough Therapy and Rare Pediatric Disease designations. Currently, the Company is exploring the use of Bucillamine for the potential treatment of infectious diseases, with an initial focus on severe influenza and COVID-19. With its acquisition of Psilocin Pharma Corp., Revive is advancing the development of Psilocybin-based therapeutics in various diseases and disorders. Revive’s cannabinoid pharmaceutical portfolio focuses on rare inflammatory diseases and the company was granted FDA orphan drug status designation for the use of Cannabidiol (CBD) to treat autoimmune hepatitis (liver disease) and to treat ischemia and reperfusion injury from organ transplantation. For more information, visit www.ReviveThera.com.

For more information, please contact:

Michael Frank
Chief Executive Officer
Revive Therapeutics Ltd.
Tel: 1 888 901 0036
Email: [email protected]
Website: www.revivethera.com

Neither the Canadian Securities Exchange nor its Regulation Services Provider has reviewed or accepts responsibility for the adequacy or accuracy of this release.

Cautionary Statement

This press release contains ‘forward-looking information’ within the meaning of applicable Canadian securities legislation. These statements relate to future events or future performance. The use of any of the words “could”, “intend”, “expect”, “believe”, “will”, “projected”, “estimated” and similar expressions and statements relating to matters that are not historical facts are intended to identify forward-looking information and are based on Revive’s current belief or assumptions as to the outcome and timing of such future events. Forward looking information in this press release includes information with respect to the the Company’s cannabinoids, psychedelics and infectious diseases programs. Forward-looking information is based on reasonable assumptions that have been made by Revive at the date of the information and is subject to known and unknown risks, uncertainties, and other factors that may cause actual results or events to differ materially from those anticipated in the forward-looking information. Given these risks, uncertainties and assumptions, you should not unduly rely on these forward-looking statements. The forward-looking information contained in this press release is made as of the date hereof, and Revive is not obligated to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as required by applicable securities laws. The foregoing statements expressly qualify any forward-looking information contained herein. Reference is made to the risk factors disclosed under the heading “Risk Factors” in the Company’s annual MD&A for the fiscal year ended June 30, 2022, which has been filed on SEDAR and is available under the Company’s profile at www.sedar.com.

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

About Ryan Allway

Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.

Farmhouse Inc. (OTCQB: FMHS) (the “Company”) announced today that the Company has its Downtown Los Angeles (“DTLA”) Cannabis retail dispensary business for sale. The DTLA dispensary is part of a 35,000 sq. ft. campus that is steps from the 10 freeway, near the up-and-coming Arts District, and close to the University of Southern California.

The dispensary comes with four licenses for retail, cultivation, distribution, and manufacturing with the opportunity to add more in the future. The cultivation business has two dry rooms, six flower rooms, and one properly sized vegetation and mom room. It is equipped with 300 luxx hps flower lights, is a gen-2 facility (considered top of the line when revamped in 2019), has a setup for salt nutrients, and additional automation.

“Farmhouse is connecting investors with an exciting opportunity to purchase a premium DTLA dispensary with a history of competitive revenue in a blossoming district of Los Angeles,” said Evan Horowitz, CEO of Farmhouse.

The DTLA dispensary is currently under the control of a court-appointed receiver, Stoneblossom LLC. Tours are available by appointment at LA Farmers Inc. 824 E 17th St., Los Angeles, CA 90021. The sale is subject to court approval.

About Farmhouse, Inc.

Farmhouse has multiple divisions, including the WeedClub Platform, a professional social platform, that enables professionals to connect, discover products and services to scale their businesses. The Company believes it has established itself as the trusted brand to connect the industry through the WeedClub Platform and its @420 Twitter handle. In December 2021, the Company launched its NFT division to connect the cannabis and NFT industries through artist partnerships, NFT licensing and generative projects.

Forward Looking Statements

The Company cautions you that statements in this press release that are not a description of historical facts are forward-looking statements. These statements are based on our current beliefs and expectations. The inclusion of forward-looking statements should not be regarded as a representation that any of our plans will be achieved. Actual results may differ from those set forth in this press release due to the risk and uncertainties inherent in our business.

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

About Ryan Allway

Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.

VANCOUVER, British Columbia, Sept. 06, 2022 (GLOBE NEWSWIRE) — Icanic Brands Company Inc. (CSE: ICAN) (OTCQB: ICNAF) (“Icanic” or the “Company”), a leading California based extraction and manufacturing cannabis company, is pleased to announce the appointment of Micah Anderson to the position of Chief Executive Officer of the Company. Mr. Anderson is a renowned cannabis expert who founded and is the CEO of LEEF Holdings Inc. (“LEEF”), which was acquired by Icanic on April 21, 2022. In conjunction with Mr. Anderson’s appointment, Brandon Kou, the Company’s current CEO has resigned from his position. The Company wishes to thank Mr. Kou for his dedication, leadership and years of service and is pleased that he will continue to be a member of the Board of Directors.

“I am looking forward to leading Icanic with the same tenacity and values that I prioritized in building LEEF into a leading Californian extraction company,” stated Mr. Anderson. “I am grateful for Brandon Kou’s years of service and significant contributions that provided the foundations on which my team and I will continue to build upon. Our simple goal is to build a leading cannabis company with great people and great results. When ICANIC acquired LEEF, they invested in more than a 12,000 sq. foot manufacturing facility and a portfolio of brands. They subscribed to our winning culture and core values and I intend on using these as pillars on which I will continue to build our Company. This new position is the next chapter of a 26 year commitment to the cannabis industry for me and I feel like we are just getting started.”

Micah Anderson is a serial entrepreneur. He founded LEEF in 2016 and acted as LEEF’s CEO, growing the business from inception to one of the largest and most respected cannabis extraction companies in the state of California. In his role as CEO, Mr. Anderson was responsible for setting and delivering on the overall strategy of LEEF and recruited a world-class team of executives, board members, and advisors to assist him as he developed significant distribution relationships with leading retailers in the U.S. He also oversaw the planning and development of the LEEF flagship campus in Northern California which has been widely recognized as one of the most sophisticated extraction facilities in North America. In building LEEF, Mr. Anderson was also able to attract private equity and institutional debt to capitalize the Company. Recognized at the Federal and State level as a thought leader in the cannabis industry, Mr. Anderson speaks regularly at conferences and advises government officials on public policy matters. Throughout his career, Mr. Anderson has demonstrated how passion, discipline, and a relentless work ethic are able to navigate through the challenges of an emerging industry, a pandemic and a challenging economic environment.

About Icanic Brands Company Inc.
ICANIC is a leading California based extraction and manufacturing cannabis company. By coupling the best California legacy operators with the experience of the traditional world, ICANIC has built a foundation to become one of North America’s premiere Cannabis companies. Our focus on creating a true platform that includes our integrated supply chain, robust manufacturing capabilities, industry leading brands and consolidated internal sales team supports future growth both organically and through M&A.

Icanic Brands Company Inc. is based in California & Nevada, the largest and most competitive cannabis markets in the world. The company’s mission is to build a great cannabis company with great people and great results. For more information, please visit the company’s website at: www.icaninc.com.

For further information about Icanic Brands, please contact the Company at:
Email: [email protected]

About LEEF Holdings
LEEF is a vertically integrated company focused on licensing, developing, and consciously bringing to market premium quality cannabis products. LEEF believes in the power of botanically based extractions and their ability to positively impact people’s lives. The company has decades of experience in all cannabis verticals and operates one of the most sophisticated manufacturing facility in the state of California and has established itself as a leader in the biodiscovery of plant-based wellness and cannabis products. The LEEF line of high-performance products can be found across the United States, the Professional Spa channel, online at leeforganics.com and in California dispensaries state-wide.

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

About Ryan Allway

Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.

VANCOUVER, British Columbia and BATTLE CREEK, Mich., Jan. 27, 2022 (GLOBE NEWSWIRE) — Eden Empire Inc. (CSE: EDEN) (the “Company” or “Eden Empire”) is pleased to announce that it has signed an agreement (the “Agreement”) with an arm’s length third-party (the “Partner”) to assist in expanding the EDEN franchise across the State of Michigan. The Partner has been involved with the construction of numerous marijuana grow, processing and dispensary facilities in the State and boasts an expansive network of contacts in the industry.

Key Notes

• 2021 Cannabis Sales in Michigan topped USD$1.79B.
• 2020 Cannabis Sales in Michigan reached USD$984M.
• 43% growth in cannabis sales year-over-year from 2020 to 2021.
• Franchisee opportunity brings massive branding exposure to the EDEN brand in a growing market.

“We are pleased to announce our Partner in Michigan to assist with expanding the EDEN footprint in Michigan. Utilizing our Partner to create advantageous opportunities for the Company is massive as this market continues to grow year-over-year.” CEO Gerry Trapasso stated, “It is an extremely exciting year ahead for all companies involved in the Michigan cannabis industry and we look forward to releasing news about onboarding potential franchisee’s in the near future.”

This news release does not constitute an offer of securities for sale in the United States. The securities ‎being offered have not been, nor will they be, registered under the United States Securities Act of ‎‎1933, as amended, and such securities may not be offered or sold within the United States absent U.S. ‎registration or an applicable exemption from U.S. registration requirements.‎

For further information or should you have any questions, please feel free to email us at [email protected].

Gerry Trapasso, CEO

Neither the Canadian Securities Exchange nor its Regulation Services Provider (as that term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this news release.

About Eden Empire

Eden Empire is in the business of investments and operations in the cannabis sector and engaging in retail cannabis sales. Eden Empire intends to expand its retail operations in Canada and to expand its business to cannabis cultivation, extraction and processing‎ and become a fully integrated cannabis product company in the United States.

Eden Empire has an award winning and established nationwide brand, including a substantial intellectual property portfolio, and a dedicated management team with extensive cannabis industry experience. Upon completion of Eden Empire’s currently intended acquisitions, and approval to operate its retail locations, the Company is expected to have a significant retail cannabis footprint in Canada and Michigan. Retail cannabis operations are an emerging sector with significant cash flow potential.

Cautionary Note Regarding Forward-Looking Statements

This release contains certain “forward looking statements” and certain “forward-looking information” as defined under applicable Canadian securities laws. Forward-looking statements and information can generally be identified by the use of forward-looking terminology such as “may”, “will”, “expect”, “intend”, “estimate”, “upon” “anticipate”, “believe”, “continue”, “plans” or similar terminology. Forward-looking statements and information include, but are not limited to, statements with respect to the gross proceeds anticipated to be received under the Third Tranche Private Placement; the future exercise of any Warrants issued under the Third Tranche Private Placement; the future price of the Company’s common shares on the CSE; the future exercise by the Company of its right to accelerate the Warrant Expiry Date; the approval of the CSE of the Third Tranche Private Placement; the Company’s future operations of retail cannabis stores in the United States and Canada; the Company expanding its business to cannabis cultivation, extraction and processing and becoming a fully integrated cannabis company in the United States; the completion of the Company’s currently intended acquisitions; the receipt of all necessary licenses and approvals to operate the Company’s retail locations; and the proposed future transactions Eden may undertake and their expected timing.

Forward-looking statements and information are based on forecasts of future results, estimates of amounts not yet determinable and assumptions that, while believed by management to be reasonable, are inherently subject to significant business, economic and competitive uncertainties and contingencies. Forward-looking statements and information are subject to various known and unknown risks and uncertainties, many of which are beyond the ability of Eden Empire to control or predict, that may cause Eden Empire’s actual results, performance or achievements to be materially different from those expressed or implied thereby, and are developed based on assumptions about such risks, uncertainties and other factors set out herein, including but not limited to: Eden Empire may not obtain the requisite regulatory approvals and may not begin operating cannabis retail or cultivation and processing operations; that the actual use of proceeds may differ from those currently stated; the inherent risks involved in the general securities markets; uncertainties relating to the availability and costs of financing needed in the future; the inherent uncertainty of production and cost estimates and the potential for unexpected costs and expenses; currency fluctuations; regulatory restrictions and the possibility for changes in laws, rules, and regulations in the industry; liability, competition, loss of key employees and other related risks and uncertainties. Eden Empire does not undertake any obligation to update forward-looking information except as required by applicable law. Such forward-looking information represents management’s best judgment based on information currently available. No forward-looking statement can be guaranteed and actual future results may vary materially. Accordingly, readers are advised not to place undue reliance on forward-looking statements.

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

About Ryan Allway

Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.

NEW YORK, Jan. 21, 2022 (GLOBE NEWSWIRE) — OTC Markets Group Inc. (OTCQX: OTCM), operator of financial markets for over 11,000 U.S. and global securities, today announced Mystic Holdings Inc. (OTCQX: MSTH), a company focused on cannabis cultivation, production and retail, has qualified to trade on the OTCQX® Best Market. Mystic Holdings Inc. upgraded to OTCQX from the Pink® market.

Mystic Holdings Inc. begins trading today on OTCQX under the symbol “MSTH.” U.S. investors can find current financial disclosure and Real-Time Level 2 quotes for the company on www.otcmarkets.com.

The OTCQX Market provides investors with a premium U.S. public market to research and trade the shares of investor-focused companies. Graduating to the OTCQX Market marks an important milestone for companies, enabling them to demonstrate their qualifications and build visibility among U.S. investors. To qualify for OTCQX, companies must meet high financial standards, follow best practice corporate governance, and demonstrate compliance with applicable securities laws.

“Mystic Holdings joining the OTCQX is a strong validation of our business strategy and prospects for continued growth,” said Michael Cristalli, President of Mystic Holdings. “As we continue to execute on our business strategy, we believe that trading on OTCQX will help drive liquidity, increase shareholder value, and allow the company more efficient access to capital markets.”

Law Offices of Thomas E. Puzzo, PLLC acted as the company’s OTCQX sponsor.

About Mystic Holdings Inc.

Mystic Holdings, Inc. is a holding company which, through its wholly-owned subsidiaries, is a fully integrated cannabis company in the State of Nevada. Since obtaining Nevada wholesale licenses for the cultivation and production of medical cannabis in 2014 and for recreational cannabis in 2016, Qualcan, LLC, Mystic’s wholly-owned operating subsidiary (“Qualcan”), has operated a highly efficient, state-of-the-art cannabis cultivation and production facility. Qualcan’s facility adheres to best practices in quality control standards and regulatory compliance that are believed to be as good as or better than those used throughout the cannabis industry. Qualcan currently wholesales its products, which include cannabis flowers, edibles and concentrates, under the trademark “Qualcan” to state-licensed dispensaries utilizing METRC, a state-mandated tracking system.

In addition to its wholesale operations, Mystic, through its wholly-owned subsidiaries Picksy, LLC and Picksy Reno, LLC (both of which also do business under the brand name Jade Cannabis Co.), operates two recreational/medical retail dispensaries (one in Clark County, Las Vegas and one in Reno). Mystic also has two additional state retail dispensary licenses (one in the City of Las Vegas and one in Carson City, the capital of Nevada), which Mystic plans to develop and open in 2022 under Jade Cannabis Co Brand.

Websites

https://investqualcan.com/
http://www.qualcan.com/
https://jadecannabisco.com/

Social Media

https://www.facebook.com/qualcanlv/
https://www.instagram.com/qualcan/?hl=en
https://www.instagram.com/jadeccreno/
https://www.instagram.com/stayjadedlv/

Contact

[email protected] (702) 960-7778

Safe Harbor Statement

Except for historical information contained herein, statements in this release may be forward-looking and made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Words such as “anticipate”, “believe”, “estimate”, “expect”, “intend” and similar expressions, as they relate to Mystic Holdings, Inc. (the “Company”) or its management, identify forward-looking statements. These statements are based on current expectations, estimates and projections about the Company’s business based, in part, on assumptions made by management. These statements are not guarantees of future performance and involve risks, uncertainties and assumptions that are difficult to predict. Therefore, actual outcomes and results may, and probably will, differ materially from what is expressed or forecasted in such forward-looking statements due to numerous factors, including those described above and those risks discussed from time to time in the Company’s filings with the Securities and Exchange Commission. Factors which could cause actual results to differ materially from these forward-looking statements include such factors as (i) the development and protection of our brands and other intellectual property, (ii) the need to raise capital to meet business requirements, (iii) significant fluctuations in marketing expenses, (iv) the ability to achieve and expand significant levels of revenues, or recognize net income, from the sale of our products and services, (v) the Company’s ability to conduct the business if there are changes in laws, regulations, or government policies related to cannabis, (vi) management’s ability to attract and maintain qualified personnel necessary for the development and commercialization of its planned products, and (vii) other information that may be detailed from time to time in the Company’s filings with the United States Securities and Exchange Commission. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

About OTC Markets Group Inc.
OTC Markets Group Inc. (OTCQX: OTCM) operates the OTCQX^® Best Market, the OTCQB^® Venture Market and the Pink^® Open Market for over 11,000 U.S. and global securities. Through our regulated OTC Link^® Alternative Trading Systems, the Company connects a diverse network of broker-dealers that provide liquidity and execution services. We enable investors to easily trade through the broker of their choice and empower companies to improve the quality of information available for their investors.

OTC Link ATS, OTC Link ECN and OTC Link NQB are each an SEC regulated ATS, operated by OTC Link LLC, a FINRA and SEC registered broker-dealer, member SIPC.

To learn more about how we create better informed and more efficient markets, visit www.otcmarkets.com.

Subscribe to the OTC Markets RSS Feed

Media Contact:
OTC Markets Group Inc., +1 (212) 896-4428, [email protected]

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

About Ryan Allway

Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.

BURLINGTON, Ontario, December 22, 2021–(BUSINESS WIRE)–Today, Rapid Dose Therapeutics Corp. (“RDT” or the “Company“) (CSE: DOSE) and McMaster University (“McMaster“) are pleased to announce that the ongoing development of an orally delivered vaccine candidate for COVID-19 has received the final installment of the Collaborative Research and Development grant, with a value of $120,000, from the Natural Sciences and Engineering Research Council of Canada (NSERC).

“We appreciate the ongoing support received from the Canadian government through NSERC as we continue to drive this important research forward,” said Mark Upsdell, CEO, Rapid Dose Therapeutics. “Global experts have called for a needle-free method of delivering vaccines for COVID-19 and many other diseases, and this research is paramount to supporting the commercialization of such an innovation.”

McMaster University research team lead Dr. Alex Adronov, PhD adds, “This installment allows us to continue our efforts in creating oral thin-film therapeutics for a variety of applications, including incorporation of vaccine components for needle-free vaccination.”

The Company is not making any express or implied claims that its product has the ability to eliminate, cure or contain COVID-19 at this time.

About Rapid Dose Therapeutics Corp.

Rapid Dose Therapeutics is a Canadian biotechnology company revolutionizing drug delivery through innovation. The Company’s flagship product QuickStrip is a thin, orally dissolvable film, that can be infused with an infinite list of active ingredients (nutraceuticals, pharmaceuticals, vaccines, cannabis) that are delivered quickly into the bloodstream resulting in rapid onset of the active ingredient.

www.rapid-dose.com

CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS:

Certain information in this news release may contain forward-looking information within the meaning of applicable securities laws. Any statements that are contained in this news release that are not statements of historical fact may be deemed to be forward-looking statements. Forward-looking statements are often identified by terms such as “may”, “should”, “anticipate”, “expect”, “potential”, “believe”, “intend”, “will”, “could”, “are planned to”, “are expected to” or the negative of these terms and similar expressions. Statements containing forward-looking information, including, without limitation, in respect of the delivery of equipment and products using the QuickStrip product delivery method, the generation of recurring revenues, as at the date of this news release, the plans, estimates, forecasts, projections, expectations or beliefs of RDT management as to future events or results and are believed to be reasonable based on information currently available to RDT management. Forward-looking statements necessarily involve known and unknown risks, including, without limitation, risks associated with general economic conditions; adverse industry events; marketing costs; loss of markets; termination of WLM agreements; future legislative and regulatory developments involving cannabis; inability to access sufficient capital from internal and external sources, and/or inability to access sufficient capital on favourable terms; the cannabis industry in Canada generally, income tax and regulatory matters; the ability to implement its business strategies; competition; currency and interest rate fluctuations and other risks. Readers are cautioned that the foregoing list is not exhaustive. There can be no assurance that statements of forward-looking information, although considered reasonable by RDT management at the time of preparation, will prove to be accurate as there can be no assurance that the plans, intentions or expectations upon which they are based will occur. Actual results and future events could differ materially from those anticipated in such forward-looking statements. Readers should not place undue reliance on forward-looking statements. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement.

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

About Ryan Allway

Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.

BURLINGTON, Ontario —Nov 24, 2021– Rapid Dose Therapeutics Corp. (“ RDT ” or the “ Company ”) ( CSE: DOSE ), a Canadian biotechnology company revolutionizing drug delivery through innovation, has completed a significant shipment of one million QuickStrip units to one of Canada’s largest cannabis companies.

Three unique formulations – 10mg THC, 20mg CBD and 20mg 1:1 ratio THC & CBD – were developed by RDT for use by medical cannabis patients following strictly controlled standard operating procedures and post-production testing requirements.

The adoption of the QuickStrip as a viable drug delivery method has confirmed and validated the technology as an effective needle free COVID-19 vaccine candidate.

“This significant order provided the opportunity for our RDT team to further streamline and perfect our manufacturing process, which will become increasingly relevant as we scale up for larger cannabis and nutraceutical production needs,” said Mark Upsdell, CEO, Rapid Dose Therapeutics. “This manufacturing and operational excellence is also ideally suited to support the research expansion of our oral vaccine candidate for COVID-19 as we get closer to starting human trials where production volume will be key.”

About Rapid Dose Therapeutics Corp.

Rapid Dose Therapeutics is a Canadian biotechnology company revolutionizing drug delivery through innovation. The Company’s flagship product QuickStrip is a thin, orally dissolvable film, that can be infused with an infinite list of active ingredients (nutraceuticals, pharmaceuticals, vaccines, cannabis) that are delivered quickly into the bloodstream resulting in rapid onset of the active ingredient.

www.rapid-dose.com

CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS :

Certain information in this news release may contain forward-looking information within the meaning of applicable securities laws. Any statements that are contained in this news release that are not statements of historical fact may be deemed to be forward-looking statements. Forward-looking statements are often identified by terms such as “may”, “should”, “anticipate”, “expect”, “potential”, “believe”, “intend”, “will”, “could”, “are planned to”, “are expected to” or the negative of these terms and similar expressions. Statements containing forward-looking information, including, without limitation, in respect of the delivery of equipment and products using the QuickStrip product delivery method, the generation of recurring revenues, as at the date of this news release, the plans, estimates, forecasts, projections, expectations or beliefs of RDT management as to future events or results and are believed to be reasonable based on information currently available to RDT management. Forward-looking statements necessarily involve known and unknown risks, including, without limitation, risks associated with general economic conditions; adverse industry events; marketing costs; loss of markets; termination of WLM agreements; future legislative and regulatory developments involving cannabis; inability to access sufficient capital from internal and external sources, and/or inability to access sufficient capital on favourable terms; the cannabis industry in Canada generally, income tax and regulatory matters; the ability to implement its business strategies; competition; currency and interest rate fluctuations and other risks. Readers are cautioned that the foregoing list is not exhaustive. There can be no assurance that statements of forward-looking information, although considered reasonable by RDT management at the time of preparation, will prove to be accurate as there can be no assurance that the plans, intentions or expectations upon which they are based will occur. Actual results and future events could differ materially from those anticipated in such forward-looking statements. Readers should not place undue reliance on forward-looking statements. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement.

View source version on businesswire.com: https://www.businesswire.com/news/home/20211124006000/en/

Contacts

Investor Contact:
Mark Upsdell, CEO
[email protected]
416-477-1052

Media Contact:
Kim Robinson
[email protected]
905-330-4055

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

About Ryan Allway

Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.

SANTA BARBARA, Calif., Nov. 17, 2021 /PRNewswire/ — Bloomios, Inc. (OTC: BLMS), CEO, Michael Hill issued the following letter to shareholders, providing an update on the Company’s developments and future growth strategy.

Bloomios Shareholder Update & Growth Strategy

Dear Shareholders, It is with immense pride that I present this update on our recent corporate activities and strategic initiatives to you.

Bloomios went public in April 2021. Bloomios was founded with the belief that high quality and affordable hemp-derived products should be accessible to those in the U.S. who need it to improve their daily activities. We are determined to become the leading hemp-derived products manufacturer, supporting the industry’s most recognized brands.

Bloomios manufactures, markets and distributes U.S. hemp-derived supplements and cosmetic products via wholesale distribution channels, manufactured by its wholly owned subsidiary Bloomios Private Label. We provide services including custom formulation, brand development and order fulfillment to a wide variety of customers including both large and small brands, chain stores, vape shops and distributors. We offer our private-label and white-label customers a large array of custom formulations and manufacturing services with over 220 hemp products across 12 categories.

Bloomios’ recent financings and cashflow have provided for the Company’s acquisition of new software and hardware to further improve our manufacturing capabilities and our operational efficiencies. More specifically, the Company purchased a new infused gummy machine, a new high-production printer, additional packaging equipment, software systems and many other items. This expansion and automation should allow the Company to increase output by 3-5 times our current manufacturing capabilities. We also continue to bolster our management team and now have 70 full-time employees.

Bloomios believes that our first full year in operation, we will hit approximately $9 million in Gross Revenue and likely breakeven or have a small loss.

Additionally, Bloomios is focused on the vertical integration of targeted brand acquisitions enabling us to address the wider consumer direct market. Through the addition of brand acquisitions, organic development, and distribution channel partnerships we intend to offer a full suite of high-quality consumer products. The Company is currently conducting due diligence on several acquisition targets.

The Bloomios management team is committed to continuing to execute our growth and acquisition strategy to increase long term shareholder value by building profitable revenue.

We value all our shareholders. If you have any questions or concerns, please do not hesitate to contact us at the following address: [email protected]

About Bloomios Inc.

Bloomios manufactures, markets and distributes U.S. hemp-derived supplements and cosmetic products through wholesale distribution channels, through its wholly owned subsidiary Bloomios Private Label. The Company provides services including custom formulation, brand development and order fulfillment to a wide variety of customers including small and major brands, chain stores, vape shops and distributors. Offering our private-label and white-label customers large collections of customizable hemp products that includes over 220 products across 12 categories in addition to custom formulation and manufacturing services. Bloomios is headquartered in Santa Barbara, California with its operations in Daytona Beach, Florida. To learn more: https://www.bloomios.com

Safe Harbor Statement:

Matters discussed in this press release contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. When used in this press release, the words “anticipate,” “believe,” “estimate,” “may,” “intend,” “expect” and similar expressions identify such forward-looking statements. Actual results, performance or achievements could differ materially from those contemplated, expressed or implied by the forward-looking statements contained herein. These forward-looking statements are based largely on the expectations of the Company and are subject to a number of risks and uncertainties. These include, but are not limited to, risks and uncertainties associated with: the sales of the company’s identity protection software products into various channels and market sectors, the issuance of the Company’s pending patent applications, COVID-19, and the impact of economic, competitive and other factors affecting the Company and its operations, markets, product, and distributor performance, the impact on the national and local economies resulting from terrorist actions, and U.S. actions subsequently; and other factors detailed in reports filed by the company.

Bloomios Contact Info:
Michael Hill, CEO
[email protected]
(805) 222-6330

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

About Ryan Allway

Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.

Schwazze Continues to widen its Colorado Expansion Strategy

DENVER, Nov. 15, 2021 /PRNewswire/ – Schwazze, (OTCQX: SHWZ) (“Schwazze” or the “Company”), announced that it has signed definitive documents to acquire the assets of Smoking Gun, LLC and Smoking Gun Land Company, LLC (“Smoking Gun”).

The Smoking Gun dispensary and assets are located on a prime retail corner on Colorado Blvd. in Glendale, Colorado in the center of the greater Denver metro area. This acquisition is part of the Company’s continuing retail expansion plan in Colorado bringing the total number of dispensaries including announced acquisitions to 20.

Total consideration for the acquisition will be $4 million in cash and 100,000 shares in Schwazze common stock upon closing. The acquisition is expected to close during the fourth quarter of 2021, subject to closing conditions and covenants customary for this type of transaction, including, without limitation, obtaining Colorado Marijuana Enforcement Division and local licensing approval.

About Schwazze
Schwazze (OTCQX: SHWZ) is building the premier vertically integrated cannabis company in Colorado and plans to take its operating system to other states where it can develop a differentiated leadership position. Schwazze is the parent company of a portfolio of leading cannabis businesses and brands spanning seed to sale. The Company is committed to unlocking the full potential of the cannabis plant to improve the human condition. Schwazze is anchored by a high-performance culture that combines customer-centric thinking and data science to test, measure, and drive decisions and outcomes. The Company’s leadership team has deep expertise in retailing, wholesaling, and building consumer brands at Fortune 500 companies as well as in the cannabis sector. Schwazze is passionate about making a difference in our communities, promoting diversity and inclusion, and doing our part to incorporate climate-conscious best practices. Medicine Man Technologies, Inc. was Schwazze’s former operating trade name. The corporate entity continues to be named Medicine Man Technologies, Inc.

Schwazze derives its name from the pruning technique of a cannabis plant to enhance plant structure and promote healthy growth.

Forward-Looking Statements
This press release contains “forward-looking statements.” Such statements may be preceded by the words “plan,” “will,” “may,”, “predicts,” or similar words. Forward-looking statements are not guarantees of future events or performance, are based on certain assumptions, and are subject to various known and unknown risks and uncertainties, many of which are beyond the Company’s control and cannot be predicted or quantified. Consequently, actual events and results may differ materially from those expressed or implied by such forward-looking statements. Such risks and uncertainties include, without limitation, risks and uncertainties associated with (i) our inability to manufacture our products and product candidates on a commercial scale on our own or in collaboration with third parties; (ii) difficulties in obtaining financing on commercially reasonable terms; (iii) changes in the size and nature of our competition; (iv) loss of one or more key executives or scientists; (v) difficulties in securing regulatory approval to market our products and product candidates; (vi) our ability to successfully execute our growth strategy in Colorado and outside the state, (vii) our ability to consummate the acquisition described in this press release or to identify and consummate future acquisitions that meet our criteria, (viii) our ability to successfully integrate acquired businesses and realize synergies therefrom, (ix) the ongoing COVID-19 pandemic, * the timing and extent of governmental stimulus programs, and (xi) the uncertainty in the application of federal, state and local laws to our business, and any changes in such laws. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company’s filings with the Securities and Exchange Commission (SEC), including the Company’s Annual Report on Form 10-K and its Quarterly Reports on Form 10-Q. Investors and security holders are urged to read these documents free of charge on the SEC’s website at http://www.sec.gov. The Company assumes no obligation to publicly update or revise its forward-looking statements as a result of new information, future events or otherwise except as required by law.

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

About Ryan Allway

Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.